Enzyme inhibition as a key target for the development of novel metal-based anti-cancer therapeutics

Anti-Cancer Agents in Medicinal Chemistry

Volumn 10, Issue 5, 2010, Pages 354-370

  Griffith, Darren ^a   Parker, James P ^a   Marmion, Celine J ^a  

^a ROYAL COLLEGE OF SURGEONS IN IRELAND   (Ireland)

Author keywords

And target; Cancer; Chaperone; Drug development; Enzyme inhibitor; Medicinal bioinorganic chemistry; Metallodrugs; Metals

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); GELATINASE A; GELATINASE B; GLUTATHIONE TRANSFERASE; GOLD DERIVATIVE; HISTONE DEACETYLASE; HISTONE DEACETYLASE 1; HISTONE DEACETYLASE 2; HISTONE DEACETYLASE 3; HISTONE DEACETYLASE 8; INTERSTITIAL COLLAGENASE; MACROPHAGE ELASTASE; MATRIX METALLOPROTEINASE; METAL COMPLEX; METAL ION; OXALIPLATIN; PHOSPHATIDYLINOSITOL 3 KINASE; PLATINUM DERIVATIVE; PROTEIN KINASE; RUTHENIUM COMPLEX; RUTHENIUM DERIVATIVE; STROMELYSIN; TELOMERASE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CRYSTAL STRUCTURE; DRUG CYTOTOXICITY; DRUG DESIGN; DRUG DNA BINDING; DRUG MECHANISM; DRUG POTENCY; DRUG SELECTIVITY; DRUG TARGETING; ENZYME INHIBITION; HUMAN; METASTASIS INHIBITION; NONHUMAN; STRUCTURE ACTIVITY RELATION;

EID: 77953885275     PISSN: 18715206     EISSN: None     Source Type: Journal    
DOI: 10.2174/1871520611009050354     Document Type: Article

References (132)

1. Orvig, C.; Abrams, M.J. Medicinal inorganic chemistry: introduction. Chem. Rev., 1999, 99(9), 2201-2204.
2. Meggers, E. Targeting proteins with metal complexes. Chem. Commun., 2009, 1001-1010.
3. Bruijnincx, P.C.A.; Sadler, P.J. New trends for metal complexes with anticancer activity. Curr. Opin. Chem. Biol., 2008, 12(2), 197-206.
4. Köpf-Maier, P.; Köpf, H. Metal Compounds in Cancer Therapy; (Organometallic titanium, Vanadium, Niobium, Molybdenum and rhenium Complexes-Early Transition Metal Antitumor Drugs). Chapman & Hall: London, 1994.
5. Köpf-Maier, P. Complexes of metals other than platinum as antitumour agents. Eur. J. Clin. Pharmacol., 1994, 47(1), 1-16.
6. Rosenberg, B.; Van Camp, L.; Krigas, T. Inhibition of cell division in escherichia coli by electrolysis products from a platinum electrode. Nature, 1965 205(4972), 698-699.
7. Guo, Z.; Sadler, P.J. Metals in medicine. Angew. Chem. Int. Ed., 1999, 38, 1512-1531.
8. Ronconi, L.; Sadler, P.J. Using coordination chemistry to design new medicines. Coord. Chem. Rev., 2007, 251(13-14), 1633-1648.
9. Galanski, M.; Jakupec, M.A.; Keppler, B.K. Update of the preclinical situation of anticancer platinum complexes: novel design strategies and innovative analytical approaches. Curr. Med. Chem., 2005, 12(8), 2075-2094.
10. Dyson, P.J.; Sava, G. Metal-based antitumour drugs in the post genomic era. Dalton Trans., 2006, 16, 1929-1933.
11. Kelland, L. The resurgence of platinum-based cancer chemotherapy. Nat. Rev., 2007, 7(8), 573-584.
12. van Rijt, S.H.; Sadler, P.J. Current applications and future potential for bioinorganic chemistry in the development of anticancer drugs. Drug Discov. Today 2009, 14(23/24), 1089-1097.
13. Louie, A.Y.; Meade, T.J. Metal complexes as enzyme inhibitors. Chem. Rev., 1999, 99(9), 2711-2734.
14. Dwyer, F.P.; Mayhew, E.; Roe, E.M.F.; Shulman, A. Inhibition of landschütz ascites tumour growth by metal chelates derived from 3,4,7,8-tetramethyl-1,10-phenanthroline. Br. J. Cancer, 1965, 19(1), 195-199.
15. Dwyer, F.; Reid, I.; Shulman, A.; Laycock, G.M.; Dixson, S. The biological actions of 1,10 phenanthroline and 2,2'-bipyridine hydrochlorides, quaternary salts and metal chelates and related compounds 1. Bacteriostatic action on selected gram-positive, gramnegative and acid-fast bacteria. Aust. J. Exp. Biol. Med. Sci., 1969, 47, 203-221.
16. Dwyer, F.P.; Gyarfas, E.C.; Wright, R.D.; Shulman, A. Effect of inorganic complex ions on transmission at a neuromuscular junction. Nature, 1957, 180(4583), 425-426.
17. Zhang, J.; Yang, P.L.; Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer, 2009, 9(1), 28-39.
18. Smalley, K.S.M.; Contractor, R.; Haass, N.K.; Kulp, A.N.; Atilla-Gokcumen, G.E.; S. Williams, D.; Bregman, H.; Flaherty, K.T.; Soengas, M.S.; Meggers, E.; Herlyn, M. An organometallic protein kinase inhibitor pharmacologically activates p53 and induces apoptosis in human melanoma cells. Cancer Res., 2007 67(1), 209-217.
19. Meggers, E. Exploring biologically relevant chemical space with metal complexes. Curr. Opin. Chem. Biol., 2007, 11(3), 287-292.
20. Debreczeni, J.É.; Bullock, A.N.; Atilla, G.E.; Williams, D.S.; Bregman, H.; Knapp, S.; Meggers, E. Ruthenium Half-Sandwich Complexes Bound to Protein Kinase Pim-1. Angewandte Chem. Int. Ed., 2006, 45(10), 1580-1585.
21. Xie, P.; Williams, D.S.; Atilla-Gokcumen, G.E.; Milk, L.; Xiao, M.; Smalley, K.S.M.; Herlyn, M.; Meggers, E.; Marmorstein, R. Structure-based design of an organoruthenium phosphatidylinositol- 3-kinase inhibitor reveals a switch governing lipid kinase potency and selectivity. Chem. Biol., 2008, 3(5), 305-316.
22. Maira, S.-M.; Stauffer, F.; Schnell, C.; García-Echeverría, C. PI3K inhibitors for cancer treatment: where do we stand? Biochem. Soc. Trans., 2009, 37, 265-272.
23. Handsley, M.M.; Edwards, D.R. Metalloproteases and their inhibitors in tumour angiogenesis. Int. J. Cancer, 2005, 115, 849-860.
24. Wallach, J. Matrix metalloproteases and cancer. Novel perspectives in the role and control of matrix metalloproteinases in tumor progression. Biochimie, 2005, 87(3-4), 241.
25. Vihinen, P.; Ala-aho, R.; Kahari, V.-M. Matrix metalloproteinases as therapeutic targets in cancer. Curr. Cancer Drug Target, 2005, 5(3), 203-220.
26. Hu, J.; Van den Steen, P.E.; Sang, Q.X.; Opdenakker, G. Matrix metalloproteinase inhibitors as therapy for inflammatory and vascular diseases. Nat. Rev. Drug Discov., 2007, 6(6), 480-498.
27. Steward, W.P.; Thomas, A.L. Marimastat: the clinical development of a matrix metalloproteinase inhibitor. Expert. Opin. Investig. Drugs, 2000, 9 (12), 2913-2922.
28. Li, N.-G.; Shi, Z.-H.; Tang, Y.-P.; Duan, J.-A. Selective matrix metalloproteinase inhibitors for cancer. Curr. Med. Chem., 2009, 16(29), 3805-3827.
29. Hall, M.D.; Failes, T.W.; Yamamoto, N.; Hambley, T.W. Bioreductive activation and drug chaperoning in cobalt pharmaceuticals. Dalton Trans., 2007, 3983-3990.
30. Failes, T.W.; Hambley, T.W. Models of hypoxia activated prodrugs: Co(III) complexes of hydroxamic acids. Dalton Trans., 2006, 1895-1901.
31. Failes, T.W.; Hambley, T.W. Towards bioreductively activated prodrugs: Fe(III) complexes of hydroxamic acids and the MMP inhibitor marimastat. J. Inorg. Biochem., 2007, 101(3), 396-403.
32. Failes, T.W.; Cullinane, C.; Diakos, C.I.; Yamamoto, N.; Lyons, J.G.; Hambley, T.W. Studies of a cobalt(III) complex of the MMP inhibitor marimastat: a potential hypoxia-activated prodrug. Chem.-Eur. J., 2007, 13, 2974-2982.
33. Sasanelli, R.; Boccarelli, A.; Giordano, D.; Laforgia, M.; Arnesano, F.; Natile, G.; Cardellicchio, C.; Capozzi, M.A.M.; Coluccia, M. Platinum complexes can inhibit matrix metalloproteinase activity: platinum-diethyl[(methylsulfinyl)methyl]phosphonate complexes as inhibitors of matrix metalloproteinases 2, 3, 9, and 12. J. Med. Chem., 2007, 50(15), 3434-3441.
34. Arnesano, F.; Boccarelli, A.; Cornacchia, D.; Nushi, F.; Sasanelli, R.; Coluccia, M.; Natile, G. Mechanistic insight into the inhibition of matrix metalloproteinases by platinum substrates. J. Med. Chem., 2009, 52(23), 7847-7855.
35. Laforgia, M.; Cerasino, L.; Margiotta, N.; Capozzi, M.A.M.; Cardellicchio, C.; Naso, F.; Natile, G. Synthesis and characterization of Platinum(II) Complexes of diethyl [(methylsulfinyl) methyl]phosphonate: potential drugs against bone tumors. Eur. J. Inorg. Chem., 2004, 17, 3445-3452.
36. Arandjelovic, S.S.; Bjelogrlic, K.S.; Malesevic, N.N.; Tesic, L.Z.; Radulovic, S.S. Antitumor activity of Ru(III) complexes carrying beta-diketonato ligands in vitro and in vivo. J. BUON, 2009, 14(2), 271-279.
37. Bergamo, A.; Gava, B.; Alessio, E.; Mestroni, G.; Serli, B.; Cocchietto, M.; Zorzet, S.; Sava, G. Ruthenium-based NAMI-A type complexes with in vivo selective metastasis reduction and in vitro invasion inhibition unrelated to cell cytotoxicity. Int. J. Oncol., 2002, 21, 1331-1338.
38. Sava, G.; Zorzet, S.; Turrin, C.; Vita, F.; Soranzo, M.R.; Zabucchi, G.; Cocchietto, M.; Bergamo, A.; Di Giovine, S.; Pezzoni, G.; Sartor, L.; Garbisa, S. Dual action of NAMI-A in inhibition of solid tumor metastasis: selective targeting of metastatic cells and binding to collagen. Clin. Cancer. Res., 2003, 9(5b), 1898-1905.
39. Rademaker-Lakhai, J.M.; van den Bongard, D.; Pluim, D.; Beijnen, J.H.; Schellens, J.H. A Phase I and pharmacological study with imidazolium-trans-DMSO-imidazole-tetrachlororuthenate, a novel ruthenium anticancer agent. Clin. Cancer Res., 2004, 10(11), 3717-3727.
40. Harley, C.B. Telomerase and cancer therapeutics. Nat. Rev. Cancer, 2008, 8(3), 167-179.
41. Tabori, U.; Dome, J.S. Telomere biology of paediatric cancer. Cancer Invest., 2007, 25(3), 197-208.
42. Autexier, C.; Lue, N.F. The structure and function of telomerase reverse transcriptase. Ann. Rev. Biochem., 2006, 75, 493-517.
43. De Cian, A.; Lacroix, L.; Douarre, C.; Temime-Smaali, N.; Trentesaux, C.; Riou, J.-F.; Mergny, J.-L. Targeting telomeres and telomerase. Biochimie, 2008, 90(1), 131-155.
44. Kieltyka, R.; Englebienne, P.; Fakhoury, J.; Autexier, C.; Moitessier, N.; Sleiman, H.F. A platinum supramolecular square as an effective G-quadruplex binder and telomerase inhibitor. J. Am. Chem. Soc., 2008, 130(31), 10040-10041.
45. Ma, D.-L.; Che, C.-M.; Yan, S.-C. Platinum(II) complexes with dipyridophenazine ligands as human telomerase inhibitors and luminescent probes for G-Quadruplex DNA. J. Am. Chem. Soc., 2009, 131(5), 1835-1846.
46. Reed, J.E.; Arnal, A.A.; Neidle, S.; Vilar, R. Stabilization of Gquadruplex DNA and inhibition of telomerase activity by squareplanar nickel(II) complexes. J. Am. Chem. Soc., 2006, 128(18), 5992-5993.
47. Dixon, I.M.; Lopez, F.; Estève, J.-P.; Tejera, A.M.; Blasco, M.A.; Pratviel, G.; Meunier, B. Porphyrin derivatives for telomere binding and telomerase inhibition. Chem Bio Chem, 2005, 6(1), 123-132.
48. Dixon, I.M.; Lopez, F.; Tejera, A.M.; Esteve, J.-P.; Blasco, M.A.; Pratviel, G.; Meunier, B. A G-quadruplex ligand with 10000-fold selectivity over duplex DNA. J. Am. Chem. Soc., 2007, 129(6), 1502-1503.
49. Reed, J.E.; Neidle, S.; Vilar, R. Stabilisation of human telomeric quadruplex DNA and inhibition of telomerase by a platinumphenanthroline complex. Chem. Commun., 2007, 4366-4368.
50. 4. J. Am. Chem. Soc., 1995, 117(23), 6273-6283.
51. 8 (en = ethylenediamine, bpy = bipyridine), which recognizes an organic molecule in aqueous media. J. Am. Chem. Soc., 1990, 112(14), 5645-5647.
52. Willermann, M.; Mulcahy, C.; Sigel, R.K.O.; Cerda, M.M.; Freisinger, E.; Sanz Miguel, P.J.; Roitzsch, M.; Lippert, B. Pyrazine as a Building Block for Molecular Architectures with PtII. Inorg. Chem., 2006, 45(5), 2093-2099.
53. Colangelo, D.; Osella, D. Telomerase inhibition and cancer: Might platinum based drugs have a future as anti-telomerase pharmacological approach? Curr. Med. Chem., 2005, 12, (26), 3091-3102
54. Furuta, M.; Nozawa, K.; Takemura, M.; Izuta, S.; Murate, T.; Tsuchiya, M.; Yoshida, K.; Taka, N.; Nimura, Y.; Yoshida, S. A novel platinum compound inhibits telomerase activity in vitro and reduces telomere length in a human hepatoma cell line. Int. J. Cancer, 2003, 104(6), 709-715.
55. Cavigiolio, G.; Benedetto, L.; Boccaleri, E.; Colangelo, D.; Viano, I.; Osella, D. Pt(II) complexes with different N-donor aromatic ligands for specific inhibition of telomerase. Inorg. Chim. Acta, 2000, 305(1), 61-68.
56. 3H-isoquinoline)] complex, a selective inhibitor of telomerase enzyme. Biometals, 2003, 16(4), 553-560.
57. Nitiss, J.L. Investigating the biological functions of DNA topoisomerases in eukaryotic cells. Biochim. Biophys. Acta, 1998, 1400(1-3), 63-81.
58. Nelson, W.G.; Liu, L.F.; Coffey, D.S. Newly replicated DNA is associated with DNA topoisomerase II in cultured rat prostatic adenocarcinoma cells. Nature, 1986, 322(6075), 187-189.
59. Brill, S.G.; Dinardo, S.; Voelkel-Meiman, K.; Sternglanz, R. Need for DNA topoisomerase activity as a swivel for DNA replication for transcription of ribosomal RNA. Nature, 1987, 326(6111), 414-416.
60. Glikin, G.C.; Blangy, D. In vitro transcription by Xenopus oocytes RNA polymerase III requires a DNA topoisomerase II activity. EMBO J., 1986, 5(1), 151-155.
61. Wang, J.C.; Lynch, A.S. Transcription and DNA supercoiling. Curr. Opin. Genet. Dev., 1993, 3(5), 764-768.
62. Newport, J.; Spann, T. Disassembly of the nucleus in mitotic extracts: membrane vesicularization, lamin disassembly, and chromosome condensation are independent processes. Cell, 1987, 48(2), 219-230.
63. Uemura, G., C.; Yanagida, M. Mitotic spindle pulls but fails to separate chromosomes in type II DNA topoisomerase mutants: uncoordinated mitosis. EMBO J., 1986, 5(5), 1003-1010.
64. Wang, J.C. Cellular roles of DNA topoisomerases: a molecular perspective. Nat. Rev. Mol. Cell. Biol., 2002, 3(6), 430-440.
65. Heck, M.M.S.; Hittelman, W.N.; Earnshaw, W.C. Differential expression of DNA topoisomerases I and II during the eukaryotic cell cycle. Proc. Natl. Acad. Sci. USA, 1988, 85, 1086-1090.
66. Chen, A.Y.; Liu, L.F. DNA topoisomerases: essential enzymes and lethal targets. Annu. Rev. Pharmacol. Toxicol., 1994, 34, 191-218.
67. Hsiang, V.H.; Lihou, M.G.; Liu, L.F. Proliferation-dependent regulation of DNA topoisomerase II in cultured human cells. Cancer Res., 1988, 48, 3230-3235.
68. Nitiss, J.L. Targeting DNA topoisomerase II in cancer chemotherapy. Nat. Rev. Cancer, 2009, 9(5), 338-350.
69. Jayaraju, D.; Vashisht Gopal, Y.N.; Kondapi, A.K. Topoisomerase II is a cellular target for antiproliferative cobalt salicylaldoxime complex. Arch. Biochem. Biophys., 1999, 369(1), 68-77.
70. Pommier, Y.; Leteurtre, F.; Fesen, M.R.; Fukimori, A.; R., B.; Solary, E.; Kohlhagen, G.; W., K.K. Cellular determinants of sensitivity and resistance to DNA topoisomerase inhibitors. Cancer Invest., 1994, 12(5), 530-542.
71. Beck, W.T.; Kim, R.; Chen, M. Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells. Cancer Chemother. Pharmacol., 1994, 34, S14-18.
72. Mokdsi, G.; Harding, M.M. Inhibition of human topoisomerase II by the antitumor metallocenes. J. Inorgan. Biochem., 2001, 83(2-3), 205-209.
73. Köpf-Maier, P.; Köpf, H. Titanocene dichloride - the first metallocene with cancerostatic activity. Angew. Chem. Int. Ed., 1979, 18(6), 477-478.
74. Köpf-Maier, P.; Köpf, H. Molybdocene dichloride as an antitumor agent. Naturforscher, 1979, 34, 1174-1176.
75. Köpf-Maier, P.; Leitner, M.; Köpf, H. Tumor inhibition by metallocenes: antitumor activity of niobocene and tungstocene dichlorides. J. Inorg. Nucl. Chem., 1980, 42, 1789-1791.
76. Köpf-Maier, P.; Köpf, H.; Wagner, W. In vitro cell growth inhibition by metallocene dichlorides. Cancer Chemother. Pharmacol., 1981, 5, 237-241.
77. Clarke, M.J. Ruthenium metallopharmaceuticals. Coord. Chem. Rev., 2003, 236(1-2), 209-233.
78. Ang, W.H.; Dyson, P.J. Classical and non-classical rutheniumbased anticancer drugs: towards targeted chemotherapy. Eur. J. Inorg. Chem., 2006, 20, 4003-4018.
79. Kostova, I. Ruthenium complexes as anticancer agents. Curr. Med. Chem., 2006, 13(9), 1085-1107
80. Alessio, E.; Mestroni, G.; Bergamo, A.; Sava, G. Ruthenium antimetastatic agents. Curr. Top. Med. Chem., 2004, 4(15), 1525-1535.
81. Hartinger, C.G.; Jakupec, M.A.; Zorbas-Seifried, S.; Groessl, M.; Egger, A.; Berger, W.; Zorbas, H.; Dyson, P.J.; Keppler, B.K. KP1019, a new redox-active anticancer agent - preclinical development and results of a clinical phase I study in tumor patients. Chem. Biodivers., 2008, 5(10), 2140-2155.
82. Hartinger, C.G.; Zorbas-Seifried, S.; Jakupec, M.A.; Kynast, B.; Zorbas, H.; Keppler, B.K. From bench to bedside - preclinical and early clinical development of the anticancer agent indazolium trans-[tetrachlorobis(1H-indazole)ruthenate(III)] (KP1019 or FFC14A). J. Inorg. Biochem., 2006, 100(5-6), 891-904.
83. 6)(dmso)]. Arch. Biochem. Biophys., 2002, 401(1), 53-62.
84. Gopal, V.Y.N.; Jeayaraju, D.; Kondapi, A.K. Inhibition of Topoisomerase II catalytic activity by two ruthenium compounds: a ligand dependent mode of action. Biochem. Pharmacol., 1999, 38(14), 4382-4388.
85. Gao, F.; Chao, H.; Zhou, F.; Chen, X.; Wei, Y.-F.; Ji, L.-N. Synthesis, GC selective DNA binding and topoisomerase II inhibition activities of ruthenium(II) polypyridyl complex containing 11- aminopteridino[6,7-f][1,10]phenanthrolin-13(12H)-one. J. Inorg. Biochem., 2008, 102(5-6), 1050-1059.
86. Chandra, M.; Sahay, A.N.; Pandey, D.S.; Tripathi, R.P.; Saxena, J.K.; Reddy, V.J.M.; Puerta, M.C.; Valerga, P. Potential inhibitors of DNA topoisomerase II: ruthenium(II) poly-pyridyl and pyridylazine complexes. Organomet. Chem., 2004, 689, 2256-2267.
87. Sharma, S.; Singh, S.K.; Pandey, D.S. Ruthenium(II) polypyridyl complexes: potential precursors, metalloligands, and topo II Inhibitors. Inorg. Chem., 2008, 47(3), 1179-1189.
88. Gopal, V.Y.N.; Jayaraju, D.; Kondapi, A.K. Topoisomerase II poisoning and antineoplastic action by DNA-binding diacetyl and dicarboxaldoxime derivatives of ferrocene. Arch. Biochem. Biophys., 2000, 376(1), 229-235.
89. Krishna, S.A.D.; Panda, G.; Kondaoi, A.K. Mechanism of action of ferrocene derivatives on the catalytic activity of topoisomerase IIα β-distinct mode of action of two derivatives. Arch. Biochem. Biophys., 2005, 438(2), 206-216.
90. Jacoby, W.B.; M., Z.D. The enzymes of detoxication. J. Biol. Chem., 1990, 265(34), 20715-20718.
91. Armstrong, R.N. Glutathione S-transferases: reaction mechanism, structure, and function. Chem. Res. Toxicol., 1991, 4(2), 131-140.
92. Hayes, J.D.; Flanagan, J.U.; R., J.I. Glutathione transferases. Annu. Rev. Pharmacol. Toxicol., 2005, 45, 51-88.
93. Nishihira, J.; Sakai, M.; Nishi, S.; Hatanaka, Y. Identification of the electrophilic substrate-binding site of glutathione S-transferase P by photoaffinity labeling. Eur. J. Biochem., 1995, 232, 106.
94. Ferrandina, G.; Scambia, G.; Damia, G.; Taglibaue, G.; Fagotti, A.; Panici, P.B.; C., M.; Mancuso, S.; Dincalci, M. Glutathione Stransferase activity in epithelial ovarian cancer: association with response to chemotherapy and disease outcome. Ann. Oncol., 1997, 8(4), 343-350.
95. Nakajima, T.; Takayama, T.; Miyanishi, K.; Nobuoka, A.; Hayashi, T.; Abe, T.; Kato, J.; Sakon, K.; Naniwa, Y.; Tanabe, H.; Niitsu, Y. Reversal of multiple drug resistance in cholangiocarcinoma by the glutathione S-transferase-specific inhibitor O1-hexadecyl-γ-glutamyl-S-benzylcysteinyl-D-phenylglycine ethylester. J. Pharmacol. Exp. Ther., 2003, 306(3), 861-869.
96. Shigeki, T.; Kiyomi, S. Glutathione transferases and cancer. Crit. Rev. Biochem. Mol. Biol., 1992, 27(4-5), 337-384.
97. Hayes, J.D.; Pulfold, J.P. The glutathione S-transferase supergene family: regulation of GST and the contribution of the isoenzymes to cancer chemoprotection and drug resistance part I. Crit. Rev. Biochem. Mol. Biol., 1995, 30(6), 445-520.
98. Dirr, H.; Reinemer, P.; Huber, R. X-ray crystal structures of cytosolic glutathione S-transferases. Implications for protein architecture, substrate recognition and catalytic function. Eur. J. Biochem., 1994, 220(3), 645-661.
99. Wilce, M.C.J.; Parker, M.W. Structure and function of glutathione S-transferases. Biochim. Biophys. Acta, 1994, 1205(1), 1-18.
100. Townsend, D.M.; Findlay, V.L.; Tew, K.D. Glutathione Stransferases as regulators of kinase pathways and anticancer drug targets. Methods Enzymol., 2005, 401, 287-307.
101. Tew, K.D.; Ronai, Z. GST function in drug and stress response. Drug Resist. Updates, 1999, 2(3), 143-147.
102. Mahajan, S.; Atkins, W.M. The chemistry and biology of inhibitors and pro-drugs targeted to glutathione S-transferases. Cell. Mol. Life Sci., 2005 62(11), 1221-1233
103. Ang, W.H.; Khalaia, I.; Allardyce, C.S.; Juillerat-Jeanneret, L.; Dyson, P.J. Rational design of platinum(IV) compounds to overcome glutathione-S-transferase mediated drug resistance. J. Am. Chem. Soc., 2005, 127(5), 1382-1383.
104. Ang, W.H.; Luca, D.L.; Chapuis-Bernasconi, C.; Juillerat-Jeanneret, L.; Bello, M.L.; Dyson, P.J. Organometallic ruthenium inhibitors of glutathione-S-transferase P1-1 as anticancer drugs. Chem Med Chem, 2007, 2(12), 1799-1806.
105. Ang, W.H.; Parker, J.L.; Luca, D.L.; Juillerat-Jeanneret, L.; Morton, C.J.; Bello, M.L.; Parker, M.W.; Dyson, P. Rational design of an organometallic glutathione transferase inhibitor. J. Angew. Chem. Int. Ed., 2009, 48(21), 3854-3857.
106. 1-N-succinimidato )] glutathione. J. Organomet. Chem., 1999, 589(1), 98-102.
107. Luger, K.; Mader, A.W.; Richmond, R.K.; F., S.D.; Richmond, T.J. Crystal structure of the nucleosome core particle at 2.8 Å resolution. Nature, 1997, 389(6648), 251-260.
108. Kouzarides, T. Chromatin modifications and their function. Cell, 2007, 128(4), 693-705.
109. Strahl, B.D.; Allis, C.D. The language of covalent histone modifications. Nature, 2000, 403(6765), 41-45.
110. Botrugno, O.A.; Santoro, F.; Minucci, S. Histone deacetylase inhibitors as a new weapon in the arsenal of differentiation therapies of cancer. Cancer Lett., 2009, 280(2), 134-144.
111. Prince, H.M.; Bishton, M.J.; Johnstone, R.W. Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol., 2009, 5(5), 601-612.
112. Bolden, J.E.; Peart, M.J.; Johnstone, R.W. Anticancer activities of histone deacetylase inhibitors. Nat. Rev. Drug Discov., 2006, 5, 769-784.
113. Minucci, S.; Pelicci, P.G. Histone Deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer. Nat. Rev. Cancer, 2006, 6, 38-51.
114. Cang, S.; Ma, Y.; Liu, D. New clinical developments in histone deacetylase inhibitors for epigenetic therapy of cancer. J. Hematol. Oncol., 2009, 2, 22.
115. Marks, P.A. Discovery and development of SAHA as an anticancer agent. Oncogene, 2007, 26(9), 1351-1356.
116. Finnin, M.S.; Donigian, J.R.; Cohen, A.; Richon, V.M.; Rifkind, R.A.; Marks, P.A.; Breslow, R.; Pavletich, N.P. Structures of a histone deacetylase homologue bound to the TSA and SAHA inhibitors. Nature, 1999, 401(6749), 188-193.
117. Schuetz, A.; Min, J.; Allali-Hassani, A.; Schapira, M.; Shuen, M.; Loppnau, P.; Mazitschek, R.; Kwiatkowski, N.P.; Lewis, T.A.; Maglathin, R.L.; McLean, T.H.; Bochkarev, A.; Plotnikov, A.N.; Vedadi, M.; Arrowsmith, C.H. Human HDAC7 harbors a class IIa histone deacetylase-specific zinc binding motif and cryptic deacetylase activity. J. Biol. Chem., 2008, 283, 11355-11363.
118. Somoza, J.R.; Skene, R.J.; Katz, B.A.; Mol, C.; Ho, J.D.; Jennings, A.J.; Luong, C.; Arvai, A.; Buggy, J.J.; Chi, E.; Tang, J.; Sang, B.-C.; Verner, E.; Wynands, R.; Leahy, E.M.; Dougan, D.R.; Snell, G.; Navre, M.; Knuth, M.W.; Swanson, R.V.; McRee, D.E.; Tari, L.W. Structural snapshots of human HDAC8 provide insights into the class I histone deacetylases. Structure, 2004, 12(7), 1325-1334.
119. Vannini, A.; Volpari, C.; Filocamo, G.; Casavola, E.C.; Brunetti, M.; Renzoni, D.; Chakravarty, P.; Paolini, C.; De Francesco, R.; Gallinari, P.; Steinkühler, C.; Di Marco, S. Crystal structure of a eukaryotic zinc-dependent histone deacetylase, human HDAC8, complexed with a hydroxamic acid inhibitor. Proc. Natl. Acad. Sci. USA, 2004, 101(42), 15064-15069.
120. Griffith, D.; Zangrando, E.; Alessio, E.; Marmion, C. A novel ruthenium nitrosyl complex which also contains a free NO-donor moiety. Inorg. Chim. Acta, 2004, 357(12), 3770-3774.
121. Griffith, D.; Lyssenko, K.; Jensen, P.; Kruger, P.E.; Marmion, C.J. Novel platinum(II) ammine hydroxamate and hydroximate complexes and the platinum-assisted hydrolysis of hydroxamic acids. Dalton Trans., 2005, 5, 956-961.
122. Griffith, D.; Krot, K.; Commiskey, J.; Nolan, K.B.; Marmion, C.J. Monohydroxamic acids and bridging dihydroxamic acids as chelators to ruthenium(III) and as nitric oxide donors: syntheses, speciation studies and nitric oxide releasing investigation. Dalton Trans., 2008, 137-147.
123. Griffith, D.; Chopra, A.; Mueller-Bunz, H.; Marmion, C.J. The reduction of platinum(IV) and palladium(IV) ions by 2,6- pyridinedihydroxamic acid. Dalton Trans., 2008, 6933-6939.
124. Griffith, D.; Devocelle, M.; Marmion, C.J. Hydroxamic Acids: Their Chemistry, Bioactivity, Solution and Solid Phase Synthesis in: Amino Acids, Peptides and Proteins in Organic Chemistry. Wiley-VCH: Weinheim, 2009.
125. Griffith, D.; Bergamo, A.; Pin, S.; Vadori, M.; Mueller-Bunz, H.; Sava, G.; Marmion, C.J. Novel platinum pyridinehydroxamic acid complexes; synthesis, characterisation, x-ray crystallographic study and nitric oxide related properties. Polyhedron, 2007, 26(16), 4697-4706.
126. Griffith, D.; Cecco, S.; Bergamo, A.; Zangrando, E.; Sava, G.; Marmion, C.J. Ruthenium(III) dimethylsulfoxide pyridinehydroxamic acid complexes as potential anti-metastatic agents; synthesis, characterisation and in vitro pharmacological evaluation. J. Biol. Inorg. Chem., 2008, 13(4), 511-520.
127. Griffith, D.; P., M.M.; Marmion, C.J. A novel anti-cancer bifunctional platinum drug candidate with dual DNA binding and histone deacetylase inhibitory activity. Chem. Commun., 2009, 6735-6737.
128. Dokmanovic, M.; Perez, G.; Xu, W.; Ngo, L.; Clarke, C.; Parmigiani, R.B.; Marks, P.A. Histone deacetylase inhibitors selectively suppress expression of HDAC7. Mol. Cancer Ther., 2007, 6(9), 2525-2534.
129. Pavelka M; Lucas MF; Russo N. On the hydrolysis mechanism of the second-generation anticancer drug carboplatin. Chem. Eur. J., 2007, 13(36), 10108-10116.
130. Hay, R.W.; Miller, S. Reactions of platinum(II) anticancer drugs. Kinetics of acid hydrolysis of cis-diammine(cyclobutane-1,1- dicarboxylato)platin(II) Carboplatin. Polyhedron, 1998, 17(13-14), 2337-2343.
131. Frew, A.J.; Johnstone, R.W.; Bolden, J.E. Enhancing the apoptotic and therapeutic effects of HDAC inhibitors. Cancer Lett., 2009, 280(2), 125-133.
132. Chow, K.H.-M.; Sun, R.W.-Y.; Lam, J.B.B.; Li, C.K.-L.; Xu, A.; Ma, D.-L.; Abagyan, R.; Wang, Y.; Che, C.-M. A gold(III) porphyrin complex with antitumor properties targets the Wnt/β-catenin pathway. Cancer Res., 2010, 70(4), 329-337.